Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma
| العنوان: | Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma |
|---|---|
| المؤلفون: | Lothar Kanz, Olga Marinets, Eckhard Thiel, Ulrich Keilholz, Lutz Uharek, Werner Hopfenmüller, Mathias Freund, H. Einsele, D. W. Beelen, Rudolf Trenschel, Jochen Casper, W. U. Knauf, Martin Schmidt-Hieber, Liisa Volin, Axel A. Fauser, Reinhard Andreesen, T Fietz, Gernot Stuhler, I. W. Blau, Tapani Ruutu |
| المصدر: | Bone Marrow Transplantation. 39:389-396 |
| بيانات النشر: | Springer Science and Business Media LLC, 2007. |
| سنة النشر: | 2007 |
| مصطلحات موضوعية: | Adult, Male, Oncology, medicine.medical_specialty, Transplantation Conditioning, medicine.drug_class, Graft vs Host Disease, Antineoplastic Agents, Neutropenia, Treosulfan, Antimetabolite, Disease-Free Survival, hemic and lymphatic diseases, Internal medicine, medicine, Humans, Transplantation, Homologous, Antineoplastic Agents, Alkylating, Busulfan, Multiple myeloma, Aged, Retrospective Studies, Transplantation, Hematology, business.industry, Retrospective cohort study, Middle Aged, medicine.disease, Surgery, Fludarabine, Female, Multiple Myeloma, business, Vidarabine, Stem Cell Transplantation, medicine.drug |
| الوصف: | In recent years, reduced-intensity conditioning (RIC) regimens before allogeneic stem cell transplantation (SCT) are increasingly used in patients not eligible for conventional conditioning. We did a retrospective, multicenter analysis to assess the feasibility of conditioning with fludarabine and treosulfan before allogeneic SCT in multiple myeloma patients. Thirty-four patients with a median age of 51.5 years were included in the analysis. All patients underwent myeloablation after conditioning followed by stable engraftment, and 29 of 31 evaluable patients (94%) showed early complete hematopoietic chimerism. Non-hematological toxicities were limited and encompassed mainly fever in neutropenia and infections. Grade II-IV acute and chronic graft-versus-host disease was observed in 33 and 39%, respectively. With a median follow-up of 708 days (range 60-1729 days), the median progression-free survival was 180 days. The treatment-related mortality was 10% on day 100 and 25% after 1 year. The median overall survival has not yet been reached. Our data indicate that conditioning with fludarabine and treosulfan before allogeneic SCT is feasible in intensively pretreated multiple myeloma patients and leads to stable engraftment and complete hematopoietic chimerism. Randomized trials are warranted to determine if this approach might be incorporated in an algorithm of multiple myeloma treatment. |
| تدمد: | 1476-5365 0268-3369 |
| DOI: | 10.1038/sj.bmt.1705605 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cae795e1aaddcbb1155cc6978075f67 https://doi.org/10.1038/sj.bmt.1705605 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....7cae795e1aaddcbb1155cc6978075f67 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14765365 02683369 |
|---|---|
| DOI: | 10.1038/sj.bmt.1705605 |